A new study today adds evidence that GLP-1 drugs, including Ozempic, Wegovy, Mounjaro and Zepbound, may cause hair loss in some patients. That finding matters if you are weighing these medications, and it comes alongside real movement elsewhere in the GLP-1 market. CVS and Walgreens have each filled 100,000 prescriptions under the $50 Medicare drug plan, MindRank's AI-built oral GLP-1 pill has reached Phase III after $23 million in spending, and Innovent is betting its 2030 growth on GLP-1 and oncology drugs.
CVS and Walgreens have each filled 100,000 prescriptions under the $50 Medicare drug plan, which shows how quickly lower-cost access to GLP-1 medications is scaling once price stops being the main barrier. That volume, reached at two major chains alone, suggests a large pool of Medicare patients who wanted these drugs but were waiting on affordability. As more plans experiment with pricing like this, prescription counts at this scale may become routine rather than notable.
That kind of demand is part of why drug developers are racing to build cheaper, easier versions of these medications. MindRank, a Chinese AI drug developer that raised $52 million in July, says its oral GLP-1 candidate has reached Phase III after roughly $23 million in R&D spending, which the company frames as evidence that AI-driven drug design can move faster and spend less than traditional development. If that holds up through the rest of trials, it would matter less for what it proves about MindRank specifically and more for what it suggests about how future GLP-1 pills, not just injections, get built.
Innovent is planning around a similar bet, expecting GLP-1 and oncology treatments to be its main revenue drivers through 2030, according to Morningstar's coverage of the company's forecast. That is a long runway for a drug class that is still relatively young in wide use, and it signals that at least one major manufacturer expects GLP-1 demand to keep compounding rather than plateau. Companies making forecasts that far out are effectively wagering that current enthusiasm for these drugs will hold, not fade.
That enthusiasm is exactly what makes it worth pausing on what scientists actually know versus what is still assumption. Coverage of GLP-1 benefits notes that researchers are still working out which effects are backed by solid evidence and which ones have gotten ahead of the data, even as public excitement about these drugs keeps growing. That gap between confirmed benefit and hype matters most for patients making decisions based on claims that have not been fully tested yet.
The hair loss findings fit squarely into that gap. A new study adds to a growing body of evidence linking GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and Zepbound to hair loss in some patients, which is not a new concern but one that keeps getting reinforced as more data comes in. This does not mean hair loss happens to everyone on these medications, but it does mean patients and doctors have another documented side effect to factor into the conversation about whether to start or continue treatment.
None of this points to a single, simple takeaway. Access to GLP-1 drugs is widening, investment in next-generation versions is accelerating, and the evidence base is still catching up to both. If you are currently on one of these medications or considering starting, I would suggest asking your doctor directly about hair loss and any other side effects that concern you, rather than relying on general enthusiasm about the drug class. The pace of growth here is real, but so is the need to keep asking what is actually proven.The pace of growth here is real, but so is the need to keep asking what is actually proven.
Key details
CVS and Walgreens have each filled 100,000 prescriptions under the $50 Medicare drug plan.
MindRank's AI-built oral GLP-1 pill hit Phase III after $23 million in R&D spending.
Innovent expects GLP-1 and oncology drugs to drive its revenue growth through 2030.
Scientists are still sorting out which GLP-1 benefits are proven and which are just hype.
A new study adds to evidence that GLP-1 drugs like Ozempic and Wegovy may cause hair loss.
Read this on GLP-1 Nation: https://glp1nation.com/edition/31